SUMMARY The plasma disappearance of intravenously administered tracer doses of tritiumlabelled 25-hydroxyvitamin D3 (250HD3) was studied in six normal subjects and in 15 patients with intestinal malabsorption. The plasma half-life was significantly shorter and the clearance rate significantly greater in the group with malabsorption compared with the controls. One explanation for this increased elimination could be interruption of an enterohepatic circulation of 250HD occurring in subjects with malabsorption and such a mechanism could account for the loss of endogenous vitamin D in these patients.
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Vitamin D deficiency and osteomalacia occur in a variety of intestinal disordersl13 and are common after jejunoileal bypass (JIB) for obesity. 5 As the major source of vitamin D in man is from endogenous synthesis in the skin, 6 10 minutes, hourly for six hours and at intervals of one to three days for 30 days. Plasma radioactivity was measured by direct scintillation counting in Nuclear Enterprises 260 scintillation fluid, using an LKB Rackbeta liquid scintillation counter. Quench correction was applied using the channels ratio method.
Plasma 250HD concentrations were measured by a competitive protein-binding assay9 using normal human serum as binding protein. The proportion of plasma radioactivity eluting as 3H-250HD3 after injection was measured by chloroform/methanol extraction and silicic acid chromatography on weekly plasma samples from the control subjects.
The measurements of plasma radioactivity were used to construct log plasma concentration/time curves for each subject and the gradient of the slope from the fourth day onwards was determined by least squares regression analysis. The relationship half-life (TA) = log2,/gradient was used to calculate the plasma half-life for each subject. Clearance rates were derived from the dose given and the area under the plasma concentration/time curve (AUC) according to the formula: Slope x dose clearance =AU AUC Differences between the control and study groups were assessed using Student's unpaired t test.
Results
The log plasma concentration/time curves demonstrated an early rapid exponential phase lasting about four hours. After three to four days, a second much slower exponential was seen, lasting for at least 30 days. The gradient of the second exponential was considered to represent elimination of the isotope after the attainment of distribution equilibrium.
The mean plasma half-life of 3H-250HD3 in the controls was 27.5±2.1 days (±SEM), compared with 14.2± 14 days in the patients with intestinal malabsorption (p<0.001) (Fig. 1) . The mean 3H-250HD3 clearance in the control group was 3.4±0-3 ml/kg/day, which was significantly lower than in the patient group (6.5±0 7 ml/kg/day; p<0-02) (Fig. 2) .
Plasma 250HD concentrations in the control group were all normal (mean 80 range 12-100 nmol/l). Five patients had 250HD levels below 12 nmol/l; of these, three were receiving 1xOHD3 therapy. The remaining nine patients had normal plasma 250HD levels (mean 62.5 nmol/l), including all three patients who were receiving parenteral vitamin D2. There was no significant correlation between the plasma 250HD intravenous bolus is unphysiological, the plasma half-life and clearance rate in this study were calculated from the plasma disappearance of the isotope after distribution equilibrium had been attained and thus our results should reflect the behaviour of the natural metabolite. It is possible that increased loss of 3H-250HD3 through the intestinal mucosa contributed to the increased plasma elimination of the metabolite in patients with intestinal disease. Reduced intraduodenal bile acid concentrations due to interruption of the enterohepatic circulation of bile acids might also contribute, although there is evidence in rats and in man that the absorption of 250HD is not bile acid dependent. 18 19 In conclusion, we have demonstrated significantly increased plasma elimination of intravenous 3H-250HD3 in patients with intestinal malabsorption. Although we have not defined the mechanism of this increased loss, it could be explained by interruption of an enterohepatic circulation of 250HD. Whatever the mechanism of the reduced plasma half-life and increased clearance of 3H-250HD3 in our patients, our findings indicate that loss of endogenous 250HD3 is increased in malabsorption and provide an explanation for the development of vitamin D deficiency and osteomalacia in patients with normal endogenous vitamin D3 synthesis who have intestinal disease, resection, or bypass.
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